Modern approaches to vaccines interchangeability
Abstract
Research findings demonstrate the possibility of replacing the vaccines, when used in accordance with the recommended dosage and administration schedule specified by the manufacturer. Control and regulatory authorities in many countries publish recommendations on how to proceed in case of the need to replace a vaccine with a similar one. However, in Russia there are no special normative documents regulating interchangeability of vaccines. It is necessary to define the concept of «interchangeability» of a vaccine as «changeability» and extend it to the possibility of continuing immunization course in a specific patient using a drug from a different manufacturer and the possibility of using vaccines with similar therapeutic indications produced by various manufacturers.
About the Authors
I. I. Snegireva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
K. E. Zatolochina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Federal Law of Russian Federation of 22.12.2014 ¹ 429-FZ, «On Amendments to the Federal Law «On Circulation of Medicines» (in Russian).
2. Borzova M. Interchangeability of biological medicines: fantasy or reality? Remedium 2014; (9): 6–13 (in Russian).
3. Mironov AN, ed. Guidance on the examination of medicines. V. 4. Moscow: Poligraf-Plus; 2014 (in Russian).
4. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3rd ed. New York: CRC Press; 2008.
5. Ozeretskovsky NA, Zatolochina KE, Snegireva II. Proposals for the prevention of adverse events when using immunobiological drugs in the Russian Federation. Bezopasnost i risk farmakoterapii 2015; (2): 25–9 (in Russian).
6. Borisevich IV, Vorobieva MS, Gayderova LA, Gorbunov MA, Davydov DS, Ignatiev GM et al. Medical immunobiological preparations. Directory. V. 1. Vaccines. Moscow: Gella-print; 2010 (in Russian).
7. Snegireva II, Zatolochina KE, Darmostukova MA, Khotova TYu, Alyautdin RN, Ozeretskovsky NA. et al. Vaccine Interchangeability. Uspehi sovremennogo estestvoznaniya 2015; (8): 43–7 (in Russian).
8. Feldman S. Interchangeability of vaccines. Pediatric Infectious Disease Journal 2001; 20(11): 23–9.
9. Public Health Agency of Canada. Canadian Immunization Guide. Principles of Vaccine Interchangeability. Available from: http://www.phac-aspc.gc.ca/publicat/cig- gci/p01-06-eng.php.
10. Hepatitis B Vaccine. Position Paper WHO. Wkly Epidemiol Rec. 2009; 84(40): 405–20.
11. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60(RR02): 1–60. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
12. CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006; 55(RR16): 1–25. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1.htm.
13. Hamborsky J, Kroger A, Wolfe S, eds. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington D. C.: Public Health Foundation; 2015. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html.
14. Public Health Agency of Canada. Canadian Immunization Guide. Principles of Vaccine Interchangeability. Available from: http://www.phacaspc.gc.ca/publicat/cig-gci/p01-06-eng.php.
15. Salisbury D, Ramsay M, eds. Public Health England. Immunization against Infectious Diseases. Part 2: The diseases, vaccinations and vaccines. 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/263311/Gre en_Book_Chapter_18_v2_0.pdf.
16. Australian Immunization Handbook. 10th ed. Part 4.5. Hepatitis B. 2015. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home.
17. Tatochenko VK, Ozeretskovsky NA, Fedorov AM. Immunoprophylaxis 2014 (reference). 12th ed. Moscow: Pediatr; 2014 (in Russian).
18. Zueva LP, ed. Preventive vaccination in health facilities. St. Petersburg; 2004 (in Russian).
19. Ozeretskovsky NA, Shalunova NV, Petruchuk EM, Indikova IN. Vaccinoprophylaxis of viral hepatitis B. Epidemiologiya i vaktsinoprofilaktika 2015; (2): 87–95 (in Russian).
20. State register of medicines. Available from: http://grls.rosminzdrav.ru/Default.aspx.
21. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders; 1999.
22. Seto D, West DJ, Gilliam RR, Ioli VA, Ferrara DK, Rich B. Antibody responses of healthy neonates to two mixed regimens of hepatitis B vaccine. Pediatr Infect Dis J. 1999; 18(9): 840–2.
23. Bush LM, Moonsammy GI, Bosciaj A. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. Vaccine 1991; (9): 807–9.
24. Kuzin SN. Vaccinoprophylaxis of Hepatitis B: successes and challenges. Vaktsinatsiya 2001; 3(15). Available from: http://medi.ru/doc/15b1504.htm (in Russian).
25. Connor BA, Phair J, Sack D, McEniry D, Hornick R, Banerjee D, et al. Randomised, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis. 2001; 32(3): 396–401.
26. Zuckerman JN, Kirkpatrick CT, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis A. J Travel Med. 1998; 5(1): 18–22.
27. Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, et al. Randomised, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2000; 19(7/8): 743–50.
28. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1996; 14(10): 982–6.
29. Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1997; 15(2): 230–6.
30. Just M, Berger R, Dreschsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces rotective antibodies after only twoweeks. Vaccine 1992; 10(11): 737–9.
31. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343(8893): 322–4.
32. Beck B, Hatz C, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminium- adsorbed hepatitis A vaccine. J Travel Med. 2004; 11(4): 201–7.
33. Sabanin YuV, Kuzin SN. Features of vaccine «Avaxim» according to domestic and foreign literature. Vaktsinatsiya 2005; (2). Available from: http://medi.ru/doc/15b3903.htm.
34. Public Health Agency of Canada. National Advisory Committee on Immunization. Canadian Immunization Guide. Principles of Vaccine Interchangeability. 2013. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/.
35. Medunitsyn NV. Medical immunobiological preparations: a handbook. V. 2. Moscow: Gella-Print; 2010.
36. Chuprinina RP, Alekseeva IA, Obukhov YuI, Soloviev EA. The effectiveness of immunization pertussis combination vaccines containing whole-cell or acellular pertussis vaccine. Biopreparaty. Profilaktika, diagnostika, lechenie 2014; (4): 4–13 (in Russian).
37. Babachenko IV. Current concepts of immunogenicity and prophylactic efficacy of acellular DTP vaccines based on complex antigens Pertussis coli. Voprosy sovremennoy pediatrii 2005; 4(5): 35–41 (in Russian).
38. Fedorov AM, Tatochenko VK. Acellular pertussis vaccine – a new stage in the fight against this infection. Voprosy sovremennoy pediatrii 2005; 4(2): 87–91 (in Russian).
39. Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000; 105(1): e11.
40. Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100(5): 772–88.
41. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 2002; 51: RR-2.
42. Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001; 20: 23–9.
43. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–16.
44. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, et al. Mass vaccination of children with pertussis toxoid: Decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001; 33: 1004–9.
45. Wirsing von Konig CH, Herden P, Palitzsch D, Schneeweiss B, Bier N. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization. Pediatr Infect Dis J. 2000; 19: 757–9.
46. Greenberg DP, Pickering LK, Senders SD, Bissey JD, Howard RA, Blatter MM, et al. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 2002; 109: 666–72.
47. Tatochenko VK. Combination vaccines. Vaktsinatsiya 2008; (5–6): 3–7 (in Russian).
Review
For citations:
Snegireva I.I., Zatolochina K.E., Darmostukova M.A., Alyautdin R.N., Romanov B.K. Modern approaches to vaccines interchangeability. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(4):3-8. (In Russ.)
Views:
766
Email this article 